NCT02455479View on ClinicalTrials.gov

Safety Study of a Disrupted Adenovirus (Ad) Serotype Cocaine Vaccine for Cocaine-dependent Individuals

PHASE1RecruitingINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

June 26, 2012

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2027

Conditions
Cocaine Dependence
Interventions
BIOLOGICAL

dAd5GNE Vaccine

dAd5GNE Vaccine or Placebo dAd5GNE Vaccine

BIOLOGICAL

Placebo

dAd5GNE Vaccine or Placebo dAd5GNE Vaccine

Trial Locations (1)

10021

RECRUITING

WCMC Department of Genetic Medicine, New York

All Listed Sponsors
collaborator

National Institute on Drug Abuse (NIDA)

NIH

lead

Weill Medical College of Cornell University

OTHER